文献速递基础与转化研究流行病学与生物统计

新型结核尿液LAM即时检测在HIV感染者中的诊断准确性:个体数据荟萃分析

Diagnostic accuracy of a novel tuberculosis point-of-care urine lipoarabinomannan assay for people living with HIV: A meta-analysis of individual in- and outpatient data.
PubMed 文献 · PLoS Med · 2020-05-01

本研究基于5项前瞻性队列研究的1595例成人HIV感染者个体数据,评估新型SILVAMP-LAM与LF-LAM检测结核的准确性。以微生物学参考标准,SILVAMP-LAM总灵敏度70.7%,显著高于LF-LAM的34.9%;CD4≤100 cells/μl者灵敏度达87.1%。SILVAMP-LAM特异度为90.9%。

要点

  • SILVAMP-LAM诊断HIV感染者结核的灵敏度显著优于LF-LAM。
  • CD4≤100 cells/μl者SILVAMP-LAM灵敏度最高,达87.1%。
  • SILVAMP-LAM特异度90.9%,略低于LF-LAM的95.3%。

核心结论

  • SILVAMP-LAM检测HIV感染者结核的灵敏度显著高于LF-LAM,尤其在CD4≤100 cells/μl患者中最高。

研究设计与样本

  • 个体参与者数据荟萃分析,纳入5项前瞻性队列研究,共1595例成人HIV感染者,61%为住院患者,中位年龄37岁。

主要发现

  • 微生物学参考标准下,SILVAMP-LAM总灵敏度70.7%(95%CI 59.0%-80.8%),LF-LAM为34.9%(95%CI 19.5%-50.9%)。
  • 复合参考标准下,SILVAMP-LAM灵敏度65.8%(95%CI 55.9%-74.6%),LF-LAM为31.4%(95%CI 19.1%-43.7%)。
  • CD4≤100 cells/μl者,SILVAMP-LAM灵敏度87.1%(95%CI 79.3%-93.6%),LF-LAM为56.0%(95%CI 43.9%-64.9%)。
  • CD4 101-200 cells/μl者,SILVAMP-LAM灵敏度62.7%(95%CI 52.4%-71.9%),LF-LAM为25.3%(95%CI 15.8%-34.9%)。
  • CD4>200 cells/μl者,SILVAMP-LAM灵敏度43.9%(95%CI 34.3%-53.9%),LF-LAM为10.9%(95%CI 5.2%-18.4%)。

关键数值与推荐

  • 微生物学参考标准下,SILVAMP-LAM特异度90.9%(95%CI 87.2%-93.7%),LF-LAM为95.3%(95%CI 92.2%-97.7%)。

临床怎么用

  • SILVAMP-LAM可作为HIV感染者结核诊断的辅助工具,尤其适用于CD4≤100 cells/μl且难以获取痰标本的患者。

局限性

  • 使用生物样本库冻存尿液而非新鲜样本,且由研究实验室熟练技术人员检测,非即时检测场景。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tuberculosis (TB) is the most common cause of death in people living with HIV (PLHIV), yet TB often goes undiagnosed since many patients are not able to produce a sputum specimen, and traditional diagnostics are costly or unavailable. A novel, rapid lateral flow assay, Fujifilm SILVAMP TB LAM (SILVAMP-LAM), detects the presence of TB lipoarabinomannan (LAM) in urine, and is substantially more sensitive for diagnosing TB in PLHIV than an earlier LAM assay (Alere Determine TB LAM lateral flow assay [LF-LAM]). Here, we present an individual participant data meta-analysis of the diagnostic accuracy of SILVAMP-LAM in adult PLHIV, including both published and unpublished data. METHODS AND FINDINGS: Adult PLHIV (≥18 years) were assessed in 5 prospective cohort studies in South Africa (3 cohorts), Vietnam, and Ghana, carried out during 2012 to 2017. Of the 1,595 PLHIV who met eligibility criteria, the majority (61%) were inpatients, median age was 37 years (IQR 30-43), 43% had a CD4 count ≤ 100 cells/μl, and 35% were receiving antiretroviral therapy. Most participants (94%) had a positive WHO symptom screen for TB on enrollment, and 45% were diagnosed with microbiologically confirmed TB, using mycobacterial culture or Xpert MTB/RIF testing of sputum, urine, or blood. Previously published data from inpatients were combined with unpublished data from outpatients. Biobanked urine samples were tested, using blinded double reading, with SILVAMP-LAM and LF-LAM. Applying a microbiological reference standard for assessment of sensitivity, the overall sensitivity for TB detection was 70.7% (95% CI 59.0%-80.8%) for SILVAMP-LAM compared to 34.9% (95% CI 19.5%-50.9%) for LF-LAM. Using a composite reference standard (which included patients with both microbiologically confirmed as well as clinically diagnosed TB), SILVAMP-LAM sensitivity was 65.8% (95% CI 55.9%-74.6%), and that of LF-LAM 31.4% (95% CI 19.1%-43.7%). In patients with CD4 count ≤ 100 cells/μl, SILVAMP-LAM sensitivity was 87.1% (95% CI 79.3%-93.6%), compared to 56.0% (95% CI 43.9%-64.9%) for LF-LAM. In patients with CD4 count 101-200 cells/μl, SILVAMP-LAM sensitivity was 62.7% (95% CI 52.4%-71.9%), compared to 25.3% (95% CI 15.8%-34.9%) for LF-LAM. In those with CD4 count > 200 cells/μl, SILVAMP-LAM sensitivity was 43.9% (95% CI 34.3%-53.9%), compared to 10.9% (95% CI 5.2%-18.4%) for LF-LAM. Using a microbiological reference standard, the specificity of SILVAMP-LAM was 90.9% (95% CI 87.2%-93.7%), and that of LF-LAM 95.3% (95% CI 92.2%-97.7%). Limitations of this study include the use of biobanked, rather than fresh urine samples, and testing by skilled laboratory technicians in research laboratories, rather than at the point of care. CONCLUSIONS: In this study, we found that SILVAMP-LAM identified a substantially higher proportion of TB patients in PLHIV than LF-LAM. The sensitivity of SILVAMP-LAM was highest in patients with CD4 count ≤ 100 cells/μl. Further work is needed to demonstrate accuracy when implemented as a point-of-care test.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Broger T, Nicol MP, Székely R, et al. Diagnostic accuracy of a novel tuberculosis point-of-care urine lipoarabinomannan assay for people living with HIV: A meta-analysis of individual in- and outpatient data. PLoS Med. 2020. PMID: 32357197. doi:10.1371/journal.pmed.1003113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。